Myomo (MYO) Beneish M-Score: -1.66 (As of Jun. 26, 2026)


MYO Myomo Inc MYO
55 GF Score
Price $1.03
GF Value $3.12
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myomo Beneish M-Score?

Myomo MYO -4.63% 55 Beneish M-Score is -1.66 as of Jun. 26, 2026. GuruFocus rates MYO with a GF Score™ of 55/100 and a GF Value™ of $3.12 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Myomo ranks worse than 86.16% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.66 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Myomo's Beneish M-Score or its related term are showing as below:

MYO' s Beneish M-Score Range Over the Past 10 Years
Min: -3.61   Med: -2.11   Max: 134.44
Current: -1.66

During the past 10 years, the highest Beneish M-Score of Myomo was 134.44. The lowest was -3.61. And the median was -2.11.


Myomo Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Myomo's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myomo Beneish M-Score Chart

Myomo Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1.21 -3.11 -1.39 -1.39

Myomo Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.78 -1.01 -2.49 -1.39 -1.66

MYO vs NSYS, NSPR, TELA: Beneish M-Score Comparison

For the Medical Devices subindustry, Myomo's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myomo Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Myomo's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Myomo's Beneish M-Score falls into.


MYO
55GF Score
Myomo Inc MYO
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myomo Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Myomo for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.97+0.528 * 1.0792+0.404 * 4.1414+0.892 * 1.0668+0.115 * 0.5924
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1643+4.679 * -0.052402-0.327 * 1.6088
=-1.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $4.83 Mil.
Revenue was 10.113 + 11.353 + 10.091 + 9.652 = $41.21 Mil.
Gross Profit was 6.902 + 7.784 + 6.442 + 6.052 = $27.18 Mil.
Total Current Assets was $25.66 Mil.
Total Assets was $36.75 Mil.
Property, Plant and Equipment(Net PPE) was $8.74 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.00 Mil.
Selling, General, & Admin. Expense(SGA) was $34.44 Mil.
Total Current Liabilities was $9.39 Mil.
Long-Term Debt & Capital Lease Obligation was $18.37 Mil.
Net Income was -3.009 + -3.814 + -3.663 + -4.632 = $-15.12 Mil.
Non Operating Income was 0.839 + 0 + 0 + 0 = $0.84 Mil.
Cash Flow from Operations was -2.197 + -1.14 + -1.829 + -8.865 = $-14.03 Mil.
Total Receivables was $4.66 Mil.
Revenue was 9.832 + 12.068 + 9.208 + 7.521 = $38.63 Mil.
Gross Profit was 6.61 + 8.615 + 6.946 + 5.326 = $27.50 Mil.
Total Current Assets was $31.10 Mil.
Total Assets was $40.87 Mil.
Property, Plant and Equipment(Net PPE) was $9.14 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.14 Mil.
Selling, General, & Admin. Expense(SGA) was $27.73 Mil.
Total Current Liabilities was $11.68 Mil.
Long-Term Debt & Capital Lease Obligation was $7.51 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4.825 / 41.209) / (4.663 / 38.629)
=0.117086 / 0.120712
=0.97

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(27.497 / 38.629) / (27.18 / 41.209)
=0.711823 / 0.659565
=1.0792

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (25.658 + 8.742) / 36.754) / (1 - (31.097 + 9.138) / 40.867)
=0.064047 / 0.015465
=4.1414

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=41.209 / 38.629
=1.0668

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.135 / (1.135 + 9.138)) / (2.004 / (2.004 + 8.742))
=0.110484 / 0.186488
=0.5924

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(34.441 / 41.209) / (27.728 / 38.629)
=0.835764 / 0.717803
=1.1643

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((18.367 + 9.385) / 36.754) / ((7.505 + 11.675) / 40.867)
=0.755074 / 0.469327
=1.6088

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-15.118 - 0.839 - -14.031) / 36.754
=-0.052402

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Myomo has a M-score of -1.66 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.66 mean?
Myomo (MYO) has a Beneish M-Score of -1.66 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Myomo and its competitors. According to the industry distribution chart, Myomo ranks #660 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 86.2%.
Is Myomo's Beneish M-Score too high?
Myomo's current Beneish M-Score is -1.66. Based on the distribution chart, Myomo ranks #660 out of 766 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Myomo has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myomo's Beneish M-Score compare to NSYS and NSPR?
According to the Medical Devices & Instruments industry distribution chart, Myomo ranks #660 out of 766 companies for Beneish M-Score. This places Myomo in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Myomo and its competitors. Myomo's current Beneish M-Score is -1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myomo stock overvalued right now?
Based on GuruFocus' analysis, Myomo (MYO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.12, compared to a current price of $1.03 — trading 67% below its estimated fair value. The current Beneish M-Score is -1.66. Myomo's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Myomo (MYO), the current Beneish M-Score is -1.66 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myomo (MYO) Overvalued in 2026?

Based on GuruFocus' analysis, Myomo stock appears to be undervalued. The current stock price of $1.03 is trading 67% below its estimated GF Value™ of $3.12. GuruFocus considers Myomo to be Possible Value Trap.

Key valuation signals for MYO:

  • Beneish M-Score: -1.66
  • GF Value™: $3.12 vs. price of $1.03 (67% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the MYO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Myomo Business Description

Other Exchanges 0M61:Germany
Address 45 Blue Sky Drive, Suite 101, Burlington, MA, USA, 01803
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
55GF Score

Get the complete analysis for MYO

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.03
Price
$3.12
GF Value